Physician profile
Jenny Phan
NPI 1124568225
$7,737.48
in general payments reported to CMS, 2019-2025
27 companies · $76.59 in 2025
The $76.59 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,010 · 2022: $2,966 · 2023: $1,340 · 2024: $344 · 2025: $76.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,451.86 | 2021-2025 | |
| Novo Nordisk INC | $843.05 | 2021-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $693.24 | 2021-2023 | |
| Abbott Laboratories | $653.67 | 2022-2025 | Freestyle Libre 3 |
| Optinose US, INC. | $527.02 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $509.88 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $465.98 | 2021-2023 | Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $454.67 | 2021 | |
| Lilly USA, LLC | $381.18 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $358.81 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.78 | 2021-2022 | |
| Esperion Therapeutics, INC. | $140.06 | 2021 | |
| Pfizer INC. | $130.93 | 2021-2023 | |
| Glaxosmithkline, LLC. | $129.72 | 2021-2023 | Shingrix |
| Merck Sharp & Dohme LLC | $115.35 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $110.79 | 2021 | |
| Sanofi-Aventis U.S. LLC | $97.02 | 2022 | |
| Corium, LLC | $95.74 | 2022-2023 | Azstarys, Azstarys |
| Amgen INC. | $92.10 | 2021-2025 | Evenity |
| Horizon Therapeutics Plc | $71.03 | 2021 | |
| Eisai INC. | $64.45 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $32.27 | 2022-2023 | Quviviq |
| Merz Pharmaceuticals, LLC | $30.93 | 2021 | |
| Nevro Corp. | $27.48 | 2022 | |
| Allergan, INC. | $18.70 | 2022 | |
| Exact Sciences Corporation | $13.83 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $1.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.